Citron Research reported that Aetna Inc. (NYSE: AET) would stop reimbursing for Questcor Pharmaceuticals' (Nasdaq: QCOR) Acthar gel except for treating infantile spasms. Shares of Aetna eased 4 cents to $39.43 while Questcor stock plummeted $24.17 to close at $26.35.